Eli Lilly and Company director Gabrielle Sulzberger reported acquiring additional Eli Lilly (LLY) equity on Form 4. On 11/17/2025, she acquired 4.853 shares of common stock that, at her election, were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after she leaves the board. On the same date, she also acquired 215.327 shares of common stock. Following these transactions, she reported beneficial ownership of 2,948.32 shares of common stock in direct ownership form.
Eli Lilly and Company director reports stock purchase. A reporting person serving as a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025 at a price of $1,021.7 per share, according to a Form 4 filing. Following this transaction, the director beneficially owns 304.271 shares of Eli Lilly common stock in direct ownership.
Eli Lilly and Company director Juan R. Luciano reported acquiring a total of 229.845 shares of Lilly common stock on 11/17/2025. One transaction covered 14.518 shares that he elected to receive as stock units under the Lilly Directors' Deferral Plan instead of cash compensation, to be settled in shares after his separation from service. A second acquisition of 215.327 shares was also reported at a price of $1,021.7 per share. Following these transactions, Luciano directly beneficially owns 16,704.141 shares of Eli Lilly common stock.
Eli Lilly & Co director William G. Kaelin, Jr. reported an acquisition of company stock on a Form 4. On 11/17/2025, he acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. After this transaction, he beneficially owned a total of 21,836.814 Eli Lilly shares, held in direct ownership.
Eli Lilly & Co (LLY) director Jamere Jackson reported acquiring common stock of the company. On 11/17/2025, the reporting person acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, coded as an acquisition transaction. Following this transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock held directly. The filing was made as a Form 4 by a single reporting person in the capacity of a company director.
Eli Lilly and Company director Mary Lynne Hedley reported acquiring additional common stock of LLY. On 11/17/2025, she acquired 9.706 shares of common stock and a separate 215.327-share award, both shown as acquisitions. The filing shows she beneficially owns 2,240.861 shares directly after these transactions, plus 98 shares held indirectly by a trust. According to the disclosure, the shares in one row were deferred in lieu of cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in common stock after she separates from service.
Eli Lilly & Co. director reports additional stock units from fee deferral
A director of Eli Lilly & Co. (LLY) reported acquiring small amounts of common stock on 11/17/2025, shown as 9.706 and 215.327 shares, through transactions coded as acquisitions. According to the explanation, these amounts represent fees that the director elected to defer in the form of stock units under the Lilly Directors' Deferral Plan instead of taking cash compensation. The filing states these deferred stock units will be settled in shares of common stock after the director separates from service. Following these transactions, the director’s beneficial ownership is listed as 74,988.689 shares held directly.
Eli Lilly & Co (LLY) director Katherine Baicker reported a new stock purchase. On 11/17/2025, she acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. Following this transaction, she directly beneficially owns 23,502.628 shares of Eli Lilly common stock.
Eli Lilly & Co. director Ralph Alvarez reported acquiring additional common stock in the company. On 11/17/2025, he acquired 11.5 shares and 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share in two separate transactions. Following these transactions, Alvarez directly beneficially owns 55,378.773 shares of common stock and indirectly owns 758 shares through a trust. Some of the acquired shares were deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after he separates from board service, aligning a portion of his director compensation with the company’s equity performance.
Lilly Endowment Inc., a 10% owner of Eli Lilly and Company (LLY), reported open-market sales of common stock. On November 17, 2025, it sold 7,789 shares at a weighted average price of $1,030.448 per share and 2,097 shares at a weighted average price of $1,031.526 per share, in multiple transactions within narrow price ranges. Following these sales, Lilly Endowment Inc. beneficially owned 92,872,191 shares of Eli Lilly common stock, held directly.